IRLAB Therapeutics - Pirepemat Phase IIb trial completes enrolment
IRLAB Therapeutics has announced the completion of patient enrolment for the Phase IIb trial (React PD) assessing pirepemat’s ability to improve balance and reduce falls in Parkinson’s disease patients (PD-Falls). The company also noted that a reduction in falls has been observed thus far in the patient population that has completed the treatment regimen, adding to the optimism about the potential outcome of the study. However, we caution that as this is a placebo-controlled, double-blind trial, it cannot yet be concluded that the effect is due to pirepemat. Nevertheless, the update is an encouraging sign for the patients enrolled in the trial, and we continue to believe that the top-line results represent a major upcoming catalyst for IRLAB. The readout is expected at the end of Q125, after all patients have finished the study and the full analysis has been completed.IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson's disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson's Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.